A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1900 participants.

Also called NCT01157455

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,900 participants (planned count) (from the registry)
Sponsor
CCRF Consulting Co., Ltd. (from the registry)
Registry
  • NCT NCT01157455
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01157455. Allocation not applicable; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization
Acronym
SEEDS
Condition
Coronary Artery Diseases
Intervention (Procedure)
Everolimus Drug Eluting Stent
Intervention (Drug)
Aspirin
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Heparin or Bivalirudin
Lead sponsor
CCRF Consulting Co., Ltd. (class: other)

Record details

Record id
cardio:ct-nct01157455
Content hash
c3494bf8ab7a65b8b479d56d29200adcd5863fbe69b1969ea1623349b6684775